Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known ...
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular ...
With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a ...
Presentation asked what clinical data management can safely delegate to AI — and what makes that delegation trustworthy ...
Learn what manufacturing challenges lie ahead, how to equip your team to protect your program from avoidable manufacturing ...
In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami ...
As biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D ...
As an amplifier of inflammatory responses, TREM-1 is implicated in IBD, cancer, arthritis, retinopathy, fibrosis, and other inflammatory conditions. Of particular relevance to IBD, targeting TREM-1 ...
Executive strategic briefing examines how China’s evolving health policy, coverage, and financing environment is reshaping ...
While increases in the interest rate from the Federal Reserve are usually bad for biotech, the sector at this moment is ...
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial • After successful Scientific Advice Meeting, Company ...
From engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results